AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms AstraZeneca has announced that the business has submitted two separate supplemental New Medication Applications to the U tadalafilmed.com http://tadalafilmed.com .S. Meals and Medication Administration for once-daily SEROQUEL XR Extended-Launch Tablets to get approval for the treating manic episodes connected with bipolar disorder and the treating depressive episodes connected with bipolar disorder. The bipolar mania submission is founded on a clinical research of once-daily treatment with SEROQUEL XR, in comparison to placebo, with a main endpoint of transformation in YMRS total score , in 316 patients experiencing bipolar mania.

Ardea’s innovative clinical-stage product applicants include lesinurad, known as RDEA594 formerly, a selective, oral URAT1 transporter inhibitor for the persistent administration of hyperuricemia in individuals with gout pain, and BAY 86-9766, known as RDEA119 formerly, a particular inhibitor of mitogen-activated ERK kinase for the treating cancer, that is being created under a worldwide license contract with Bayer Health care AG. About AstraZeneca AstraZeneca is a worldwide, innovation-powered biopharmaceutical business with a principal concentrate on the discovery, development and commercialisation of prescription medications for gastrointestinal, cardiovascular, neuroscience, inflammation and respiratory, oncology and infectious disease.